Pavmed inc. (PAVM)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

General and administrative expenses

2,333

1,724

1,914

1,692

1,941

1,397

1,590

1,380

1,330

1,263

1,319

1,499

1,103

1,350

959

517

589

274

293

130

Research and development expenses

2,254

1,519

1,405

1,450

1,370

1,171

1,148

563

558

704

701

656

606

578

355

179

141

264

67

16

Total operating expenses

4,588

3,243

3,319

3,143

3,311

2,568

2,738

1,943

1,888

1,967

2,021

2,156

1,710

1,928

1,314

696

730

538

360

146

Loss from operations

-4,588

-3,243

-3,319

-3,143

-3,311

-2,568

-2,738

-1,943

-1,888

-1,967

-2,021

-2,156

-1,710

-1,928

-1,314

-696

-

-

-

-

Other income (expense)
Debt extinguishments

-1,164

-406

-258

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense - Senior Secured Note

-

-

-

-

-

707

500

500

362

362

0

0

-

0

-

-

-

-

-

-

Change in fair value - Senior Secured Convertible Note

217

-379

161

558

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Modification - Series Z Warrant Agreement

-

-

-

-

-

0

-1,140

-

-

0

-1,140

-

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series A-1 Warrants

-

-

-

-

0

0

0

349

-

0

0

0

-

-

-

-

-

-

-

-

Series W Warrants Exchange Offer - April 5, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series W Warrants

-

-

-

-

-

0

-766

-

-

0

-766

-

-

-

-

-

-

-

-

-

Unit Purchase Options (UPOs) Exchange Offer - August 22, 2018 - incremental fair value - UPO-Z issued-upon-exchange of UPO-W

-

-

-

-

-

2

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Loss - Series A Preferred Stock Units private placement

-

-

-

-

-

0

0

-

0

0

0

3,124

-

0

0

-

-

-

-

-

Change in fair value - Series A Warrants derivative liability

-

-

-

-

0

0

0

96

-2,623

2,215

-748

-786

-

0

0

-

-

-

-

-

Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability

-

-

-

-

0

0

0

-64

-719

583

-283

-224

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Other income (expense), net

-1,965

-27

-419

-559

-3,610

-709

-2,407

-881

-1,469

-3,161

1,031

2,113

-

0

0

-

-

-

-

-

Loss before provision for income tax

-6,554

-3,271

-3,739

-3,703

-6,922

-3,278

-5,146

-2,825

869

-5,129

-989

-4,270

-1,710

-1,928

-1,314

-696

-

-

-

-

Provision for income taxes

-

-

-

-

-

0

0

-

-

0

0

0

0

0

0

0

-

-

-

-

Net loss - before noncontrolling interest

-

-3,271

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss - before noncontrolling interest

-

-

-3,739

-3,703

-

-3,278

-5,146

-2,825

-

-5,129

-989

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interest

-310

-186

-145

-168

-

-32

81

-

-

0

0

-

-

-

-

-

-

-

-

-

Net loss - attributable to PAVmed Inc.

-6,243

-3,084

-3,593

-3,534

-6,831

-3,246

-5,065

-2,825

869

-5,129

-989

-4,270

-1,710

-1,928

-1,314

-696

-730

-538

-360

-146

Less: Series B Convertible Preferred Stock dividends earned

69

68

66

65

64

64

63

10

-

0

0

0

-

-

-

-

-

-

-

-

Less: Series A-1 Convertible Preferred Stock dividends earned

-

-

-

-

0

0

0

25

73

6

0

0

-

0

-

-

-

-

-

-

Less: Series A Convertible Preferred Stock dividends earned

-

-

-

-

0

0

0

26

-17

52

51

26

-

0

0

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock

-

-

-

-

0

0

1,453

-726

-

-

-

-

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock

-

-

-

-

-

0

0

-

-

0

0

0

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - increase to additional paid-in capital - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock

-

-

-

-

0

0

0

-199

-

0

0

0

-

-

-

-

-

-

-

-

Deemed dividend Series A-1 Convertible Preferred Stock

-

-

-

-

-

0

-

-

-

182

-

-

-

-

-

-

-

-

-

-

Deemed dividend Series A-1 Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Net loss attributable to PAVmed Inc. common stockholders

-6,313

-3,153

-3,660

-3,600

-6,896

-3,311

-5,128

-3,414

309

-5,370

-1,040

-4,296

-1,710

-1,928

-1,314

-696

-

-

-

-

Net loss per share - attributable to PAVmed Inc. - basic and diluted

-0.18

-0.10

-0.13

-0.13

-0.26

-0.12

-0.26

-0.17

0.07

-0.38

-0.08

-0.32

-0.13

-0.14

-0.10

-0.06

-0.06

-0.05

-0.03

-0.01

Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted

-0.19

-0.10

-0.13

-0.13

-0.24

-0.12

-0.27

-0.21

0.03

-0.40

-0.08

-0.32

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic and diluted

35,003

31,030

27,605

27,149

26,732

26,538

19,289

16,544

13,989

13,332

13,331

13,330

13,317

13,310

12,995

12,250

12,250

11,138

10,856

10,856